|
A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN® vaccine in healthy adults.
PMID 36460535 · Vaccine · 2023-Jan-09
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
PMID 36495881 · Lancet · 2023-Jan-07
主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
|
H
L
B
|
旧查询独有 |
excludedsafety_or_economic_primary_endpoint |
pending
0 Figure · 0 Panel · risk -
|
|
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
PMID 36493791 · Lancet · 2023-Jan-07
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
PMID 36442484 · Lancet · 2023-Jan-07
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial.
PMID 36069202 · Clin Infect Dis · 2023-Jan-06
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial.
PMID 36068705 · Clin Infect Dis · 2023-Jan-06
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Lecanemab in Early Alzheimer's Disease.
PMID 36449413 · N Engl J Med · 2023-Jan-05
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small cell lung cancer reduces hippocampal atrophy compared to conventional PCI.
PMID 35640975 · Neuro Oncol · 2023-Jan-05
The record describes a randomized Phase III trial of HA-PCI versus conventional PCI for small cell lung cancer, which meets oncology, human, randomized, and phase criteria. However, it is ineligible because the intervention is non-drug-only (comparing radiotherapy techniques), and the primary endpoint is not a time-to-event efficacy measure (e.g., OS, PFS, DFS) but rather neuroimaging atrophy and cognitive outcomes. The deterministic review correctly identified the absence of time-to-event signal and drug intervention.
|
H
L
B
|
旧查询独有 |
excludedmodel_adjudicated_excluded |
pending
0 Figure · 0 Panel · risk -
|
|
An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
PMID 36404171 · Vaccine · 2023-Jan-04
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Cost-effectiveness of Novel Macrophage-Regulating Treatment for Wound Healing in Patients With Diabetic Foot Ulcers From the Taiwan Health Care Sector Perspective.
PMID 36633847 · JAMA Netw Open · 2023-Jan-03
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.
PMID 36719158 · Clin J Am Soc Nephrol · 2023-Jan-01
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Effects of Disease-Worsening Following Withdrawal of Etanercept or Methotrexate on Patient-Reported Outcomes in Patients With Rheumatoid Arthritis: Results From the SEAM-RA Trial.
PMID 36459119 · J Clin Rheumatol · 2023-Jan-01
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Examining the Effect of Direct Patient Care for Medical Physicists: A Randomized Prospective Phase III Trial.
PMID 36289039 · Int J Radiat Oncol Biol Phys · 2023-Jan-01
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN.
PMID 36001000 · Clin Orthop Relat Res · 2023-Jan-01
The study is a Phase III randomized drug trial in oncology, but the primary endpoint analyzed in this report is pain relief, a patient-reported outcome, not a time-to-event efficacy endpoint required for inclusion.
|
H
L
B
|
旧查询独有 |
excludedmodel_adjudicated_excluded |
pending
0 Figure · 0 Panel · risk -
|
|
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.
PMID 38251504 · Lancet Rheumatol · 2023-Jan
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.
PMID 36651532 · Headache · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Evaluation of the efficacy and safety of NVP-1203 and aceclofenac in patients with acute low back pain and muscle spasm: A randomized, double-blind, active-controlled, parallel, multicenter, phase 3 clinical trial.
PMID 36647880 · Eur Rev Med Pharmacol Sci · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
PMID 36529811 · Paediatr Drugs · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
PMID 36512175 · Am J Clin Dermatol · 2023-Jan
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.
PMID 36484969 · CNS Drugs · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment.
PMID 36463826 · Epilepsy Behav · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Retention, efficacy, tolerability, and quality of life during long-term adjunctive brivaracetam treatment by number of lifetime antiseizure medications: A post hoc analysis of phase 3 trials in adults with focal seizures.
PMID 36435010 · Epilepsy Behav · 2023-Jan
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Adherence, safety and potential effectiveness of a home-based Radio-Taiso exercise program in older adults with frailty: A pilot randomized controlled trial.
PMID 36426763 · Geriatr Gerontol Int · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Psychosocial outcomes of repeated treatment of seizure clusters with midazolam nasal spray: Results of a phase 3, open-label extension trial.
PMID 36410152 · Epilepsy Behav · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
High accuracy of recombinant fusion protein early secretory antigenic target protein 6-culture filtrate protein 10 skin test for the detection of tuberculosis infection: a phase III, multi-centered, double-blind, hospital-based, randomized controlled trial.
PMID 36400376 · Int J Infect Dis · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.
PMID 36396519 · Thromb Res · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and Safety of the Adjuvant Use of Probiotic Bacillus clausii Strains in Pediatric Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study.
PMID 36380186 · Paediatr Drugs · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2).
PMID 36321799 · Neurourol Urodyn · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview Substudy Results.
PMID 36287306 · Am J Clin Dermatol · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
PMID 36272026 · Adv Ther · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies.
PMID 36264430 · Am J Clin Dermatol · 2023-Jan
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Lower injection-site reactions and long-term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113: Results from a post-hoc analysis of a double-blind, randomized, phase III comparative study and its open-label extension in patients with rheumatoid arthritis.
PMID 36253032 · Int J Rheum Dis · 2023-Jan
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
PMID 36240801 · Lancet Gastroenterol Hepatol · 2023-Jan
The trial is for Crohn's disease (non-oncology). Even if considered oncology, the endpoints are not time-to-event efficacy outcomes (OS, PFS, etc.) as defined by the adjudication criteria.
|
H
L
|
旧查询独有 |
excludedmodel_adjudicated_excluded |
pending
0 Figure · 0 Panel · risk -
|
|
Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
PMID 36196777 · Epilepsia · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood.
PMID 36179986 · Transplant Cell Ther · 2023-Jan
The record describes an analysis of health-related quality of life from a randomized phase III trial, but it is not a primary or key secondary report of a time-to-event efficacy endpoint.
|
H
L
B
|
旧查询独有 |
excludedmodel_adjudicated_excluded |
pending
0 Figure · 0 Panel · risk -
|
|
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
PMID 36115523 · J Am Acad Dermatol · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study.
PMID 35977863 · Allergol Int · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Placement of an intrauterine device within 48 hours after early medical abortion-a randomized controlled trial.
PMID 35970199 · Am J Obstet Gynecol · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.
PMID 35961761 · Ann Rheum Dis · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
A Double-Blind Randomized Placebo-Controlled Phase 3 Trial of Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection.
PMID 35863486 · Chest · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease.
PMID 35842121 · Clin Gastroenterol Hepatol · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
PMID 35820547 · J Am Acad Dermatol · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Celecoxib-tramadol co-crystal in patients with moderate-to-severe pain following bunionectomy with osteotomy: A phase 3, randomized, double-blind, factorial, active- and placebo-controlled trial.
PMID 35686380 · Pain Pract · 2023-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2).
PMID 36855099 · BMC Med · 2023-Feb-28
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial.
PMID 36849996 · BMC Res Notes · 2023-Feb-28
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
PMID 36849969 · Alzheimers Res Ther · 2023-Feb-28
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
PMID 36774935 · Lancet · 2023-Feb-25
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years.
PMID 36829111 · BMC Infect Dis · 2023-Feb-24
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
[Efficacy and safety of various doses of hybutimibe monotherapy or in combination with atorvastatin for primary hypercholesterolemia: a multicenter, randomized, double-blind, double-dummy, parallel-controlled phase Ⅲ clinical trial].
PMID 36789598 · Zhonghua Xin Xue Guan Bing Za Zhi · 2023-Feb-24
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial.
PMID 36322937 · Blood · 2023-Feb-23
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|